606
Views
5
CrossRef citations to date
0
Altmetric
Articles

A multi-arm phase Ib/II study designed for rapid, parallel evaluation of novel immunotherapy combinations in relapsed/refractory acute myeloid leukemia

ORCID Icon, ORCID Icon, , , , , , ORCID Icon, , , , , ORCID Icon, , ORCID Icon, ORCID Icon, , , , , , , , , & show all
Pages 2161-2170 | Received 22 Dec 2021, Accepted 30 Mar 2022, Published online: 20 Apr 2022

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

William L Redmond. (2023) Challenges and opportunities in the development of combination immunotherapy with OX40 agonists. Expert Opinion on Biological Therapy 23:9, pages 901-912.
Read now
Aleksandra Gołos, Joanna Góra-Tybor & Tadeusz Robak. (2023) Experimental drugs in clinical trials for acute myeloid leukemia: innovations, trends, and opportunities. Expert Opinion on Investigational Drugs 32:1, pages 53-67.
Read now

Articles from other publishers (3)

Gill Norman, Thomas Mason, Jo C Dumville, Peter Bower, Paul Wilson & Nicky Cullum. (2022) Approaches to enabling rapid evaluation of innovations in health and social care: a scoping review of evidence from high-income countries. BMJ Open 12:12, pages e064345.
Crossref
Maddalena Marconato, Joseph Kauer, Helmut R. Salih, Melanie Märklin & Jonas S. Heitmann. (2022) Expression of the immune checkpoint modulator OX40 indicates poor survival in acute myeloid leukemia. Scientific Reports 12:1.
Crossref
Tristan E. Knight, Holly Edwards, Soheil Meshinchi, Jeffrey W. Taub & Yubin Ge. (2022) “FLipping” the Story: FLT3-Mutated Acute Myeloid Leukemia and the Evolving Role of FLT3 Inhibitors. Cancers 14:14, pages 3398.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.